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Identity 
Other names: TAK1; TGF1a 




MAP3K7/TAK1 gene spans 71 kb of DNA and 
contains 17 exons and 16 introns. Exon 1 contains the 
5' UTR of the mRNA and encodes 40 amino acid of N-
terminal of the protein. Exons 2 to 8 encode the kinase 
domain. Exon 17 encodes the carboxyl end of the 
TAK1 protein and contains the 3'UTR. Exon 12 and 
exon 16 are alternative exons.  
The promoter is located between 799 bp and 1215 bp 
upsteam of the exon 1. The promoter has the character 
of housekeeping genes: the absence of TATA box, the 
presence of CpG island and SP1 binding sites. 
Transcription 
Four alternatively spliced transcripts encoding 4 
distinct isoforms because of the presence or absence of 
alternative exons 12 or/and 16 are detected. 
Variant A: It lacks an in-frame coding segment, exon 
12. 
Variant B: This variant contains both alternative exons 
12 and 16 and encodes the longest isoform. 
Variant C: Variant C lacks the exon 16 resulting in a 
frame shift in exon 17. The resulting isoform C has a 
distinct and shorter C terminus when compared with 
variants A and B. 
Variant D: Variant D lacks both exons 12 and 16. 
The regulation of the TAK1 mRNA alternative splicing 
is tissue specific. The different variants of TAK1 may 




A: The 17 exons are shown as black vertical bars. The exon numbers are shown on top of each exon. The CpG island is shown as a 
white box. The positions of exons in the cDNA are 1-282, 283-393, 394-459, 460-505, 506-644, 645-768, 770-898, 899-1029, 1030-1111, 
1112-1242, 1243-1372, 1373-1453, 1454-1518, 1519-1624, 1625-1686, 1687-1802, and 1803-2850. The sizes (in base pairs) of intron 1 
to 16 are 14956, 3073, 6891, 1407, 3451, 2913, 1278, 1499, 2290, 659, 2625, 8150, 12553, 4358, 695, and 1765, respectively. 
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B: MAP3K7 transcripts. 
 
Pseudogene 




MAP3K7/TAK1 isoform B contains 606 amino acids 
(aa) and has a predicted molecular weight of 67 kDa, 
isoform D contains 491 aa and has a predicted 
molecular weight of 53.7 kDa, isoform C contains 518 
aa and has a predicted molecular weight of 56.7 kDa, 
and isoform A contains 579 aa and has a predicted 
molecular weight of 64 kDa. 
Description 
MAP3K7/TAK1 was first identified by screening a 
mouse cDNA library for clones that could act as 
MAPKKKs. The mouse TAK1 cDNA encodes a 579-
amino acid protein. The mouse TAK1 protein contains 
a 300-residue COOH-terminal domain and a putative 
NH2-terminal protein kinase catalytic domain. 
The kinase domain has approximately 30% identity to 
the catalytic domains of Raf-1 and MEKK1. Kondo et 
al. (1998) cloned human TAK1 from lung cDNA 
library by screening with mouse TAK1 sequence. 
Human TAK1 gene encodes a 579-amino-acid protein. 
The hTAK1 gene has 91.8% identity with the mTAK1 
gene at the nucleotide level and has 99.3% to that at the 
amino acid level. Human TAK1 mRNA with a size of 
3.0 kb was observed to express in all the tissues 
examined by Northern blotting. Kondo et al. (1998) 
found 2 isoforms of TAK1. Isoform 2 had an insertion 
of 27 amino acids between amino acids 403 and 404 of 
isoform 1 which corresponded to the mTAK1 sequence 
previously identified by Yamaguchi et al. (1995). The 
two isoforms were expressed at different ratios. 
Isoform 1 (Variant A) was predominantly expressed in 
brain, heart and spleen while the isoform 2 (Variant B) 
was preferentially in the kidney. 
Independently, Sakurai et al. (1998) cloned hTAK1 as 
well as two alternatively spliced isoforms. Human 
TAK1a (Variant A) has 99.3% identity to murine 
TAK1. TAK1b (Variant B) had an insertion of 27 
amino acids and TAK1c had a deletion of 39 amino 
acids in the carboxyl-terminal region. The catalytic 
domains of these three isoforms were 100% identical to 
that of murine TAK1. The mRNA for TAK1a and 
TAK1b were expressed in Hela, Jurkat and THP1 cells 
and TAK1a mRNA expessed predominantly in these 
cell lines. TAK1c mRNA (Variant C) was expressed 
only in Hela cells. Northern blot analysis revealed the 
expression of TAK1 mRNA in all the human tissues 
examined with the size of 3.2 and 5.7 kb. Dempsey et 
al. (2000) identified a fourth splice variant of TAK1 
called TAK1d (Variant D). TAK1d lacked the two 
alternative exons and encoded a 491 amino acid 
protein. TAK1a and b were the most abundant forms in 
most tissues examined. The carboxyl-end variant 
TAK1 proteins were unlikely to interfere with the 
catalytic activity of TAK1 or its interaction with TAB1 
since both of which involve the N terminus, but may 
affect its interaction with TAB2 which associates with 
the carboxyl-ends of the TAK1 proteins. 
Expression 
TAK1 was ubiquitously expressed in all tissues. 
TAK1a (variant A) was the most abundant form in 
heart, liver, skeletal muscle, ovary, spleen and 
peripheral blood mononuclear cells; TAK1b (Variant 
B) was more abundant in brain, kidney, prostate and 
small intestine; TAK1c (Variant C) is ubiquitously 
expressed and predominantly in prostate; and TAK1d 
(Variant D) existed in most tested tissues as a minor 
variant. 
Localisation 
TAK1 is mostly localized in cytoplasm. 
Function 
TAK1 is a member of the serine/threonine protein 
kinase family. It can be activated by transforming 
growth factor-beta (TGF-b) and TAK1 deletion mutant 
missing the N-terminal 22 amino acid is constitutively 
active. In response to TGF-b, TAK1 can phosphorylate 
and activate MAP kinase kinases MKK3, MKK4 and 
MKK6. TAK1 can activate NF-kB in the presence of 
TAB1. TAK1 is also involved in pro-inflammatory 
cytokines signaling by activa-ting two kinase pathways. 
One is a MAPK cascade that leads to the activation of 
JNK and the other is IkB kinase cascade that causes the 
activation of NF-kB. It was shown that TRAF6 is a 
signal mediator that activates IKK and JNK in response 
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to pro-inflammatory cytokine interleukin 1. The 
activation of IKK by TRAF6 requires two intermediary 
factors, TRAF6-regulated IKK activator 1 (TRIKA1) 
and TRIKA2. TRIKA1 is an ubiquitin-conjugating 
enzyme complex consisted of Ubc13 and Uev1A. 
TRIKA1, together with TRAF6, catalyze the formation 
of a Lys63-linked polyubi-quitin chain that mediates 
IKK activation. TRIKA2 is composed of TAK1, TAB1 
and TAB2. The activation of TAK1 kinase complex is 
dependent on its polyubiquitination by the TRAF6-Ubc 
complex and phosphorylation of several residues within 
the kinase activation loop by yet-to-be identified 
kinases. The ubiquitinated TAK1 can phosphorylate 
IKKbeta specifically at S177 and S181. Mutation 
analysis revealed that a point mutation in the ATP-
binding domain of TAK1 (K63W), which abolished its 
kinase activity, was unable to activate IKK. TAK1 was 
activated by auto-phosphorylation on Ser192 and dual
phosphorylation of Thr-178 and Thr-184 residues 
within the activation loop. Mutation of a conserved 
serine residue (Ser192) in the activation loop betwe n 
kinase domain VII and VIII abrogated the 
phosphorylation and activation of TAK1. TAK1 is 
linked to TRAFs by two adaptor proteins TAB2 and 
TAB3. The interaction of TAB2/TAB3 with TAK1 is 
essential for the activation of signaling pathway 
mediated by IL-1. 
It was shown that protein phosphatase 2Cepsilon 
(PP2Cepsilon) inhibited the IL-1 and TAK1 induced 
activation of MKK4-JNK or MKK3-p38 signaling 
pathway. PP2Cepsilon inactivated TAK1 by 
associating with and dephosphorylating TAK1. A type-
2A phosphatase, protein phosphatase 6 (PP6), was also 
identified as a TAK1-binding protein. PP6 repressed 
TAK1 activity by dephos-phorylating Thr187. 
Homology 
Human TAK1-like (TAKL) gene encoded a 242 amino 
acid protein which shared a homology with human 
TAK1. The amino acid sequences of TAK1 were 
highly conserved between human and mouse. 
Mutations 
Note 




TGF-b1 signaling is involved in tumor angiogenesis 
and metastasis by regulating matrix proteosis. MMP-9 
is an important component of these TGF-b1 responses. 
TAK1 is important for TGF-b1 regulation of MMP9 
and metastatic potential of breast cancer cell line 
MDA-MB231. Suppression of TAK1 reduces the 
expression of MMP9 and tumor cell invasion. TAK1 
and NFkB are required for the human MCF10A-CA1a 
breast cancer cells to undergo invasion in response to 
TGF-b. A novel TAB1:TAK1: IKKb: NFkB signaling 
axis forms aberrantly in breast cancer cells and enabl s 
oncogenic signaling by TGF-b. 
Lung cancer 
Note 
Mutation analysis: Study on 39 lung cancer specimens 
and 16 lung cancer cell lines indicated that hTAK1 was 
not a frequent target for genetic alternations in lu g 
cancer. 
TAK1 variant D activated by siRNAs of specific 
sequences leads to down stream activation of p38 
MAPK and JNK but not NFkB pathway. In human lung 
cancer cell line NCI-H460 the activation of these 
pathway cause cell cycle arrest and apoptosis. It 
suggests that TAK1 D may be a new and promising 
therapeutic target for the treatment of non-small ce
lung cancer. Telomeres are essential elements at the 
ends of chromosomes that contribute to chromosomal 
stability. The length of the telomere is maintained by 
the telomerase holoenzyme, which contains the revers  
trans-criptase hTERT as a major enzymatic subunit. 
The activity of telomerase is absent in most normal 
human cells because of the downregulation of the 
hTERT transcript resulting in the shortening of 
telomeres after each replicative cycle. However, in 
immortalized cells and cancer cells, the telomere 
lengths are maintained through an increase in hTERT 
expression. TAK1 can repress the transcription of 
hTERT in A549 human lung adenocarcinoma cell line 
and this repression is caused by recruitment of HDAC 
to the hTERT promoter. 
Cervical carcinoma 
Note 
Tumor necrosis factor (TNF)-related apoptosis-
inducing ligand (TRAIL), a member of TNFa ligand 
family, induces apoptosis in a variety of tumor cells. 
TRAIL induced the delayed phospho-rylation of TAK1 
in human cervical carcinoma HeLa cells. TRAIL 
induced apoptosis was enhanced by downregulation of 
TAK1. 
Head and neck squamous cell 
carcinoma 
Note 
NFkB was constitutively activated in head and neck 
squamous cell carcinoma (HNSCC). Constitutive 
activation of NFkB in HNSCC was caused by 
constitutive activation of IKK. Constitutive activa-tion 




Exercise/joint mobility has therapeutic potency for 
inflammatory joint diseases such as rheumatoid and 
osteoarthritis. The biomechanical signals at 
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physiological magnitudes are potent inhibitors of 
inflammation induced by NFkB activation in 
fibrochondrocytes. The biomechanical signals exert 
anti-inflammatory effects by inhibiting phosphory-
lation of TAK1. 
JNK is essential for metalloproteinase (MMP) gene 
expression and joint destruction in inflammatory 
arthritis. TAK1 is an upstream kinase of JNK. TAK1 
play an important role for the IL1b induced JNK 
activation and the JNK induced gene expression in 
fibroblast-like synoviocytes (FLSs). It suggests that 
TAK1 is a potential therapeutic target to modulate 
synoviocyte activation in rheumatoid arthritis (RA). 
Inflammation 
Note 
Pro-inflammatory molecules lipopolysaccharide and 
Interleukin 1 trigger the activation of TAK1, which in 
turn activates multiple kinase JNK, p38, IKK and 
PKB/Akt which are important components of kinase 
cascades involved in inflammation. Thus TAK1 plays 
an important role in inflammation. 
Human airway epithelial cells 
Note 
Act1/TRAF6/TAK1-mediated NF-kB activation 
stimulated by IL-17A regulates gene induction in 
human airway epithelial cells. Dominant negative 
TAK1 reduces IL-17A induced gene expression. 
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